Literature DB >> 11413331

Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.

A L Maerz1, H E Drummer, K A Wilson, P Poumbourios.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) entry into cells is mediated by the surface-exposed envelope protein (SU) gp120, which binds to cellular CD4 and chemokine receptors, triggering the membrane fusion activity of the transmembrane (TM) protein gp41. The core of gp41 comprises an N-terminal triple-stranded coiled coil and an antiparallel C-terminal helical segment which is packed against the exterior of the coiled coil and is thought to correspond to a fusion-activated conformation. The available gp41 crystal structures lack the conserved disulfide-bonded loop region which, in human T-lymphotropic virus type 1 (HTLV-1) and murine leukemia virus TM proteins, mediates a chain reversal, connecting the antiparallel N- and C-terminal regions. Mutations in the HTLV-1 TM protein gp21 disulfide-bonded loop/chain reversal region adversely affected fusion activity without abolishing SU-TM association (A. L. Maerz, R. J. Center, B. E. Kemp, B. Kobe, and P. Poumbourios, J. Virol. 74:6614-6621, 2000). We now report that in contrast to our findings with HTLV-1, conservative substitutions in the HIV-1 gp41 disulfide-bonded loop/chain reversal region abolished association with gp120. While the mutations affecting gp120-gp41 association also affected cell-cell fusion activity, HIV-1 glycoprotein maturation appeared normal. The mutant glycoproteins were processed, expressed at the cell surface, and efficiently immunoprecipitated by conformation-dependent monoclonal antibodies. The gp120 association site includes aromatic and hydrophobic residues on either side of the gp41 disulfide-bonded loop and a basic residue within the loop. The HIV-1 gp41 disulfide-bonded loop/chain reversal region is a critical gp120 contact site; therefore, it is also likely to play a central role in fusion activation by linking CD4 plus chemokine receptor-induced conformational changes in gp120 to gp41 fusogenicity. These gp120 contact residues are present in diverse primate lentiviruses, suggesting conservation of function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413331      PMCID: PMC114387          DOI: 10.1128/JVI.75.14.6635-6644.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes.

Authors:  A Pinter; R Kopelman; Z Li; S C Kayman; D A Sanders
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

4.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

5.  Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence.

Authors:  P Poumbourios; K A Wilson; R J Center; W El Ahmar; B E Kemp
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

8.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

9.  The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells.

Authors:  S Hallenberger; M Moulard; M Sordel; H D Klenk; W Garten
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

10.  Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.

Authors:  L Wu; G LaRosa; N Kassam; C J Gordon; H Heath; N Ruffing; H Chen; J Humblias; M Samson; M Parmentier; J P Moore; C R Mackay
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  30 in total

1.  Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41.

Authors:  Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

3.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

4.  Restraining the conformation of HIV-1 gp120 by removing a flexible loop.

Authors:  Sophia Rits-Volloch; Gary Frey; Stephen C Harrison; Bing Chen
Journal:  EMBO J       Date:  2006-09-28       Impact factor: 11.598

5.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

6.  The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160.

Authors:  Jayita Sen; Amy Jacobs; Haiqing Jiang; Lijun Rong; Michael Caffrey
Journal:  Protein Sci       Date:  2007-06       Impact factor: 6.725

Review 7.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

8.  Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41.

Authors:  Avraham Ashkenazi; Mathias Viard; Yael Wexler-Cohen; Robert Blumenthal; Yechiel Shai
Journal:  FASEB J       Date:  2011-03-23       Impact factor: 5.191

9.  Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.

Authors:  Beatriz Pacheco; Nirmin Alsahafi; Olfa Debbeche; Jérémie Prévost; Shilei Ding; Jean-Philippe Chapleau; Alon Herschhorn; Navid Madani; Amy Princiotto; Bruno Melillo; Christopher Gu; Xin Zeng; Youdong Mao; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

10.  Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.

Authors:  Vani G S Narasimhulu; Anna K Bellamy-McIntyre; Annamarie E Laumaea; Chan-Sien Lay; David N Harrison; Hannah A D King; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.